✉news HealthMedicine first seen 5 h ago, last just now, peak #18
Insilico Medicine reports 40% response rate for AI-designed cancer drug
Original: Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026
Insilico Medicine announced results for ISM6331, a pan-TEAD inhibitor designed using generative AI, at ESMO 2026. In heavily pretreated mesothelioma patients, the drug achieved a 40% objective response rate at the 130 mg dose. The data highlight growing interest in AI-discovered cancer therapies and offer a potential option for patients with limited remaining treatments.
Why now: The ESMO 2026 presentation of strong clinical results for an AI-designed drug is drawing attention from the oncology and biotech communities.
Insilico MedicineISM6331ESMO 2026mesothelioma
Rank over time, top of the chart is #1. 4 snapshots from 5 h ago to just now.
Evidence
- Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026 · EurekAlert!
- Insilico Medicine reports 40% ORR at 130 mg for Pan-TEAD inhibitor ISM6331 designed using generative AI in heavily pretreated mesothelioma at ESMO 2026 · EurekAlert!
API: https://socialmediatrends-api.osmike.com/v1/trends/3786667